| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT00609180 Details | 2016-04-13 Interventional | 3 | 272 | Antioxidants Acute Lung Inju… Lung Injury Respiratory Dis… Respiratory Dis… Syndrome Respiratory Dis… | The Omega arm of this study was stopped for futility. The EDEN arm continues to recruit
patients as a separate independent study. - | |||
| NCT01941615 2013-000298-62 Details | 2016-04-11 Interventional | 1 | 18 | Ethinyl Estradi… Ethinyl estradi… Healthy | - This trial was prematurely discontinued during the run-in period. During the run-in period, subjects were to receive Microgynon® once daily for 21 to 49 days. The investigational products Deleobuvir + faldaprevir were not administered. | |||
| NCT01426555 Details | 2016-04-11 Interventional | 2/3 | 70 | Zoledronic Acid Osteoporosis | Incomplete data set & analysis No Data Safety Monitor Board established for this project. Incomplete data set and analysis. | |||
| NCT01023880 Details | 2016-04-11 Interventional | 1/2 | 62 | Delanzomib Multiple Myelom… Neoplasms, Plas… | - - | |||
| NCT02529241 Details | 2016-04-08 Interventional | 1 | 12 | Delpazolid Oxazolidinones Healthy | - - | |||
| NCT02150499 Details | 2016-04-08 Interventional | 3 | 18 | Albuterol Asthma Respiratory Asp… | - - | |||
| NCT00227344 Details | 2016-04-08 Interventional | 4 | 129 | Anti-Arrhythmia… Atrial Fibrilla… | Study prematurely terminated due to randomization imbalance. The study was terminated early due to randomization imbalance. The relatively small number of subjects enrolled limited the amount of data available for analysis. Because the study did not reach its targeted enrollment, the study is underpowered. | |||
| NCT02446028 Details | 2016-04-07 Interventional | 2 | 13 | Insulin Lispro Diabetes Mellit… | IND Withdrawn - | |||
| NCT01628913 2012-000769-19 Details | 2016-04-07 Interventional | 2 | 62 | Dactolisib Everolimus Adenoma, Islet … Neuroendocrine … Pancreatic Neur… | This trial was terminated based on an interim analysis as BEZ235 did not demonstrate a
progression free survival advantage to everolimus treatment. Trial terminated based on the results of a pre-planned interim analysis of the primary OM ( which demonstrated BEX235 not having improved PFS (progression free survival) vs everolimus)..The secondary OM analyses were not conducted | |||
| NCT01222819 Details | 2016-04-06 Interventional | 4 | 120 | Lenograstim Neutropenia Leukemia | Physycians' refusal to continue the study - | |||
| NCT00663234 Details | 2016-04-06 Interventional | 1/2 | 28 | Atorvastatin Hyperlipidemias Hyperlipoprotei… HIV Infections Hyperlipidemia | The study was prematurely discontinued due to administrative reasons. Target enrollment was 40 participants (20 in each age cohort). However, the study was prematurely discontinued due to administrative reasons, having enrolled only 28 participants (21 participants aged 10 to 14 and 7 participants aged 15 to 23). | |||
| NCT00383799 2005-001505-25 Details | 2016-04-06 Interventional | 4 | 302 | Amiodarone Procainamide Tachycardia Tachycardia, Ve… Ventricular Tac… Wide QRS Tachyc… | Steering Committee decision after inclusion of 74 patients after 6 years and very slow
inclusion rate - | |||
| NCT00219778 Details | 2016-04-06 Interventional | 2 | - | Mifepristone Leiomyoma Myofibroma | - - | |||
| NCT02137343 Details | 2016-04-04 Interventional | 3 | 34 | Capecitabine Rilotumumab Stomach Neoplas… Gastric Cancer | All Amgen sponsored AMG102 clinical studies were terminated following a pre-planned Data
Monitoring Committee safety review of study 20070622. - | |||
| NCT01230827 NCT01777399 2009-015019-42 Details | 2016-04-04 Interventional | 3 | 173 | Golimumab Methotrexate Arthritis Arthritis, Juve… Juvenile Idiopa… | Trial has failed to meet primary - and major secondary endpoints - | |||
| NCT00960531 Details | 2016-04-01 Interventional | 2 | 160 | Saponin QA-21V1 Alzheimer Disea… | - In 2013 the sponsor decided that ACC-001 would not be further developed in mild to moderate Alzheimer's disease, study drug administration was discontinued, and remaining participants were followed for safety for up to 6 months after last injection. | |||
| NCT00462384 Details | 2016-04-01 Interventional | 3 | 39 | Epoetin Alfa Anemia Kidney Diseases Renal Insuffici… | Strategic decision unrelated to safety or efficacy This study was terminated early due to strategic decision unrelated to safety or efficacy. | |||
| NCT00608881 Details | 2016-03-30 Interventional | 3 | 609 | Coenzyme Q10 Ubiquinone Huntington Dise… Huntington's Di… | Futility analysis failed to showed likelihoo of benefit of CoQ 2400 mg/day. An interim analysis for futility revealed a conditional power of < 5% for the primary analysis, and the trial was halted in July, 2014. Only data collected prior to this time were included in the final analyses. | |||
| NCT02720120 2004-002132-26 Details | 2016-03-28 Interventional | 1/2 | 175 | Ocrelizumab Arthritis Arthritis, Rheu… Rheumatoid Arth… | The overall benefit risk profile of ocrelizumab was not favorable in RA - | |||
| NCT02106364 Details | 2016-03-28 Interventional | 3 | 0 | Insulin Insulin Glargin… Insulin, Globin… Diabetes Mellit… Diabetes Mellit… | Lilly's decision to cancel this trial is due to regulatory uncertainty in China. - |